TEVA:NYE-Teva Pharmaceutical Industries Limited American Depositary Shares (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 17.96

Change

+1.03 (+6.08)%

Market Cap

USD 38.25B

Volume

0.02B

Analyst Target

USD 12.19
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Its products include Copaxone, Azilect and Provigil.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-12 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-1.51 (-0.93%)

USD 66.32B
HLN Haleon plc

-0.26 (-2.43%)

USD 45.41B
TAK Takeda Pharmaceutical Co Ltd A..

-0.47 (-3.31%)

USD 43.84B
RDY Dr. Reddy’s Laboratories Ltd..

+0.17 (+1.22%)

USD 11.39B
ELAN Elanco Animal Health

+0.20 (+1.56%)

USD 4.28B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.10 (-1.32%)

USD 3.25B
BHC Bausch Health Companies Inc

-0.11 (-2.30%)

USD 1.60B
CPHI China Pharma Holdings Inc

-0.15 (-6.71%)

USD 4.61M
YCBD cbdMD Inc

+0.06 (+6.32%)

USD 1.44M
EBS Emergent Biosolutions Inc

+0.04 (+0.68%)

N/A

ETFs Containing TEVA

FLWR:SW 5.80 % 0.00 %

N/A

N/A
ISRPF iShares Public Limited Co.. 5.39 % 0.00 %

+0.34 (+0%)

USD 2.22B
ALFI 0.00 % 0.88 %

N/A

N/A
EIS iShares MSCI Israel ETF 0.00 % 0.59 %

+0.19 (+0%)

N/A
GNRX 0.00 % 0.55 %

N/A

N/A
GWL 0.00 % 0.34 %

N/A

N/A
ISRA VanEck Israel ETF 0.00 % 0.60 %

+0.36 (+0%)

USD 0.09B
ISRL:LSE 0.00 % 0.00 %

N/A

N/A
TASE:LSE 0.00 % 0.00 %

N/A

N/A
IS3T:F iShares IV Public Limited.. 0.00 % 0.00 %

-0.18 (0%)

N/A
IS3T:XETRA iShares MSCI World Size F.. 0.00 % 0.00 %

+0.33 (+0%)

N/A
ISRCF iShares V Public Limited .. 0.00 % 0.00 %

+0.95 (+0%)

N/A
ISRHF iShares V Public Limited .. 0.00 % 0.00 %

+0.14 (+0%)

N/A
ISRUF iShares V Public Limited .. 0.00 % 0.00 %

+0.18 (+0%)

N/A
ISRZF iShares II Public Limited.. 0.00 % 0.00 %

N/A

N/A
ISRIF 0.00 % 0.00 %

N/A

N/A
ISRVF iShares Public Limited Co.. 0.00 % 0.00 %

N/A

N/A
ISRWF iShares II Public Limited.. 0.00 % 0.00 %

N/A

N/A
ISRNF 0.00 % 0.00 %

N/A

N/A
ISRRF 0.00 % 0.00 %

N/A

N/A
FLWG:LSE 0.00 % 0.00 %

N/A

N/A
FLWR:LSE 0.00 % 0.00 %

N/A

N/A
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
BLUM:F 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.51% 21% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.51% 21% F 10% F
Trailing 12 Months  
Capital Gain 6.40% 50% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.40% 50% F 55% F
Trailing 5 Years  
Capital Gain 62.53% 85% B 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.53% 77% C+ 47% F
Average Annual (5 Year Horizon)  
Capital Gain 13.26% 73% C 76% C+
Dividend Return 13.26% 73% C 72% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 42.79% 40% F 19% F
Risk Adjusted Return 30.98% 73% C 48% F
Market Capitalization 38.25B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.40 N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector